Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Nivolumab With Radiation for Brain Metastases in RCC
NCT06132945Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2023
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabozantinib in metastatic renal cell carcinoma (mRCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Percent of enrolled patients who are able to tolerate treatment at 56 days. Started Nov 2023; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT06132945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132945.